08.09.2017 • Whitepaper

Talent Recruitment Strategies that take advantage of the Brexit

Who says the Brexit is no good? Talent Recruitment Strategies that take...
Who says the Brexit is no good? Talent Recruitment Strategies that take advantage of the Brexit!

When the UK joined the European Economic Community (EEC) on 1 January 1973, nobody could imagine that quite exactly 40 years later, in January 2013, then Prime Minister David Cameron announced a referendum on EU membership before the end of 2017. What started as the attempt to regain political power in his political party ended on 23 June 2016 with a 51.9% vote to leave the EU. Since then UK politics did not much to develop a roadmap for leaving the EU, but raised the level of confusion and even further incited insecurities of the future of the UK inside their country and throughout the world.

What is next?
A separation is not the solution to globalization challenges –and what made the UK great some hundred years ago will not be the solution to today’s challenges. What matters today is integration within a global context to be relevant in the future. The British will be very busy for the next years to handle their relatively nonsensical EU exit in a complicated way –and the longer politics in the UK do no seriously prepare for the Brexit, the more likely a hard and economically devastating break will be the outcome for the UK, but not necessarily for the rest of the world. If you cannot change it, you should try to take advantage of it. So, isn’t there a positive aspect of the Brexit?

Want to know more? Just download the whitepaper.
 

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read